Jounce Therapeutics has filed a patent for methods of treating infectious diseases and enhancing vaccine effectiveness using an ICOS agonist, such as an anti-ICOS agonist antibody. The patent claims a method of treating an infectious disease by administering an ICOS agonist to a subject. GlobalData’s report on Jounce Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jounce Therapeutics, personalized cancer vaccines was a key innovation area identified from patents. Jounce Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treating infectious diseases with an icos agonist
A recently filed patent (Publication Number: US20230151098A1) describes a method for treating infectious diseases and enhancing the effectiveness of vaccines. The method involves administering an ICOS agonist to a subject.
The first claim of the patent outlines a method of treating an infectious disease by administering a therapeutically effective amount of an ICOS agonist to the subject. The second claim focuses on enhancing the effectiveness of a vaccine against an infectious disease by administering an ICOS agonist to the subject concurrently with or after the administration of the vaccine.
The patent also specifies the use of ICOS agonists in the treatment of bacterial diseases caused by various bacteria, including Staphylococcus aureus, Pseudomonas aeruginosa, Streptococcus pneumoniae, and others. Specifically, the method can be used to treat bacterial diseases caused by Streptococcus pneumoniae, with the vaccine PneumoVax 34 (Merck) being mentioned as a potential vaccine to be used in conjunction with the ICOS agonist.
Furthermore, the patent highlights the use of ICOS agonists in the treatment of viral diseases caused by viruses such as human papillomavirus (HPV), human immunodeficiency virus (HIV), dengue virus, zika virus, and others. The patent specifically mentions the use of ICOS agonists in the treatment of SARS-CoV-2, the virus responsible for COVID-19. The method can be used in subjects who have tested positive for SARS-CoV-2, whether they have exhibited symptoms or not. Symptoms such as fever, cough, shortness of breath, loss of sense of taste and/or smell, fatigue, and body aches are mentioned as potential indicators of SARS-CoV-2 infection.
The patent also includes claims related to the use of ICOS agonists in the treatment of viral diseases caused by influenza viruses and varicella zoster virus. Seasonal and pandemic influenza vaccines, as well as the Zostavax vaccine (Merck), are mentioned as potential vaccines to be used in conjunction with the ICOS agonist.
The patent further specifies that the ICOS agonist can be an anti-ICOS agonist antibody, with specific antibodies such as vopratelimab, BMS-986226, KY1044, KY1055, and GSK3359609 being mentioned. Dosage ranges and administration frequencies are also provided.
Lastly, the patent mentions that the method can be used in subjects of various age groups, including those who are at least 60, 65, 70, 75, or 80 years old. Additionally, subjects with immune disorders such as Wiskott-Aldrich syndrome, X-linked thrombocytopenia (XLT), CVID, hypogammaglobulinemia, and idiopathic CD4 lymphopenia can benefit from the method.
In summary, the patent describes a method of treating infectious diseases and enhancing vaccine effectiveness by administering an ICOS agonist to a subject. The method can be applied to bacterial and viral diseases, including SARS-CoV-2, influenza viruses, and varicella zoster virus. The use of specific ICOS agonists, vaccines, dosages, and administration frequencies are outlined, along with the potential benefits for different age groups and subjects with immune disorders.
To know more about GlobalData’s detailed insights on Jounce Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
